Planned Obsolescence
These companies have mastered the art of creating products designed for replacement. Our analysts have carefully selected businesses that benefit from predictable upgrade cycles, generating reliable revenue streams as consumers continually refresh their purchases.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Apple, Inc.
AAPL
Current price
$230.56
The company's frequent release of new iPhone models with incremental hardware and software updates encourages a consistent upgrade cycle among its loy...
The company's frequent release of new iPhone models with incremental hardware and software updates encourages a consistent upgrade cycle among its loyal customer base.
Electronic Arts Inc.
EA
Current price
$170.68
Electronic Arts consistently releases annual versions of its major sports franchises that require a new purchase to access updated rosters and feature...
Electronic Arts consistently releases annual versions of its major sports franchises that require a new purchase to access updated rosters and features.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
We've identified companies that strategically engineer products with finite lifespans to ensure future sales. This controversial but profitable business model creates predictable revenue cycles as consumers regularly upgrade to newer versions, making these stocks potentially reliable performers.
What You Need to Know
These companies span multiple industries—from consumer tech and gaming to apparel and home appliances. Their common thread is a business approach that encourages regular replacement purchases, creating recurring revenue streams that can potentially withstand broader market fluctuations.
Why These Stocks
We've selected industry leaders who have proven track records of successfully launching new iterations that drive consumer demand. These companies benefit from technological advancement and shifting trends, which accelerate perceived obsolescence and stimulate demand for next-generation products.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+12.27%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 12.27% over the next year.
Stocks Rated Buy by Analysts
8 of 14 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 6.8% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
Predictable Revenue Cycles
Companies in this group benefit from built-in replacement cycles, creating more reliable revenue streams than businesses that depend on one-time purchases.
Tech Acceleration Boost
The rapid pace of AI and software advancements is shortening product lifecycles, potentially accelerating the upgrade cycles these companies depend on.
Consumer Loyalty Premium
Many of these companies have built strong brand ecosystems that keep customers returning for upgrades, potentially creating more stable long-term returns.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.